Partnering
Aeviant is open to conversations with scientists, research organizations and funding partners whose capabilities align with physiology-led small-molecule discovery.
An initial enquiry should identify the organization, the relevant capability or funding, and the proposed scope. Initial messages must remain non-confidential. Enquiries may also be sent directly to [email protected].
Areas of interest
Aeviant’s internal work currently centres on scientific strategy, target characterization and computational research. The company is interested in external capabilities that can move defined research questions into chemistry and experimental testing. Depending on the work, this may include medicinal chemistry, synthesis, functional assays, electrophysiology, in vivo pharmacology or scaled compute. These capabilities are not represented as internal.
Relevant discussions may also involve GPCR pharmacology, receptor-state biology, assay development, molecular modelling, translational neuroscience, academic collaboration or non-dilutive support for early research. Aeviant is not announcing a formal financing round.
Confidentiality
Technical discussion beyond the public information on this website requires a signed non-disclosure agreement. Initial enquiries must remain non-confidential and should not include unpublished mechanisms, structures, chemical information, experimental plans or other proprietary material.